title: [A case of recurrent gastric cancer successfully treated with S-1 oral administration].
abstract: This report describes a case of recurrent gastric cancer successfully treated with S-1 oral administration. A 77-year old female patient underwent distal gastrectomy for gastric cancer, followed by adjuvant chemotherapy with tegafur-uracil (UFT). However, 1 year after surgical resection, recurrence in the lymph node of the hepatic hilum was diagnosed by abdominal computed tomography. The patient was treated with S-1 alone after refusing in travenous infusion chemotherapy. Three months after treatment, the size of the target lesion decreased significantly, and a complete response was seen on imaging examination during the 2 years of chemotherapy treatment. One year and 5 months after the discontinuation of chemotherapy, recurrence was noted again. Although supportive care was eventually provided to the patient, S-1 oral administration was resumed that resulted in tumor growth control for>6 months. In this patient, S-1 treatment was effective in tumor growth suppression without deteriorating the patient's quality of life (QOL). Further studies are needed to identify patients for whom S-1 therapy is optimal treatment.
authors.affiliation: Cancer Treatment Center, Kochi Medical School Hospital.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Maeda
authors.forename: Ken
authors.initials: K
authors.lastname: Okamoto
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Usui
authors.forename: Akihiro
authors.initials: A
authors.lastname: Kawamura
authors.forename: Seihei
authors.initials: S
authors.lastname: Tamura
authors.forename: Atsunori
authors.initials: A
authors.lastname: Takeshita
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid